Canaccord Genuity Group Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock

Belite Bio (NASDAQ:BLTE – Get Free Report) had its target price upped by research analysts at Canaccord Genuity Group from $303.00 to $314.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group‘s target price suggests a potential upside of 92.86% from the company’s current price.

BLTE has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $245.00 target price on shares of Belite Bio in a research note on Thursday, October 15th. Zacks Research lowered shares of Belite Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 18th. Mizuho boosted their price objective on Belite Bio from $221.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday. Leerink Partners boosted their price target on shares of Belite Bio from $185.00 to $215.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Cantor Fitzgerald boosted their price target on Belite Bio from $266.00 to $270.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $226.91.

View Our Latest Stock Analysis on Belite Bio

Belite Bio Price Performance

NASDAQ:BLTE traded down $1.54 during trading hours on Monday, hitting $162.81. 134,608 shares of the company were exchanged, compared to its average volume of 190,552. Belite Bio has a 52-week low of $105.88 and a 52-week high of $200.00. The company’s 50 day moving average price is $160.88 and its 200-day moving average price is $160.24. The stock has a market capitalization of $6.56 billion, a price-to-earnings ratio of -59.96 and a beta of -1.19.

Belite Bio (NASDAQ:BLTE – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.19. On average, equities analysts predict that Belite Bio will post -3.08 earnings per share for the current year.

Insider Transactions at Belite Bio

In other news, CFO Hao-Yuan Chuang sold 49,433 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $187.64, for a total value of $9,275,608.12. Following the completion of the transaction, the chief financial officer owned 44,000 shares of the company’s stock, valued at approximately $8,256,160. This represents a 52.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yu-Hsin Lin sold 74,435 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $187.71, for a total value of $13,972,193.85. Following the completion of the transaction, the chief executive officer directly owned 96,134 shares in the company, valued at approximately $18,045,313.14. This trade represents a 43.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 168,330 shares of company stock valued at $31,969,118. Corporate insiders own 13.29% of the company’s stock.

Institutional Trading of Belite Bio

Several hedge funds and other institutional investors have recently modified their holdings of BLTE. Marshall Wace LLP bought a new position in Belite Bio during the third quarter valued at approximately $15,282,000. State Street Corp raised its stake in shares of Belite Bio by 6.9% in the third quarter. State Street Corp now owns 34,044 shares of the company’s stock valued at $5,781,000 after acquiring an additional 2,196 shares during the period. Alberta Investment Management Corp bought a new stake in shares of Belite Bio during the third quarter valued at approximately $4,076,000. Candriam S.C.A. purchased a new position in shares of Belite Bio in the 3rd quarter worth approximately $10,711,000. Finally, Vise Technologies Inc. acquired a new stake in Belite Bio during the third quarter worth about $217,000. Institutional investors own 0.53% of the company’s stock.

Belite Bio Company Profile

(Get Free Report)

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.

Further Reading

Analyst Recommendations for Belite Bio (NASDAQ:BLTE)

Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.